PT 141 Bremelanotide
What is PT 141 Bremelanotide?
PT 141 Bremelanotide is a revolutionary new drug that is used in the treatment of women who have diminished sexual desire as a result of premenopausal symptoms and also in men who suffer from sexual dysfunction. PT 141 Bremelanotide is a synthetic peptide hormone capable of stimulating sexual activity and desire. PT 141 Bremelanotide is a type of hormone receptor agonist called melanocortin, which increases sexual desire by inciting the release of dopamine by the hypothalamus in the brain.
Initially, treating sexual dysfunction was not the intended purpose of PT 141 Bremelanotide. Rather, PT 141 Bremelanotide was created as an offshoot from synthetic peptide Melanotan II, an oral sunless tanner, which darkens the pigmentation of the skin. An early study of Melanotan II showed that 90% of male test subjects exhibited erections as well as an increase in sexual arousal from using Melanotan II. Subsequent research showed the synthetic hormone stimulated the nervous system in controlling sexual desire. Popular sexual dysfunction drugs Cialis and Viagra function in a different manner by working on the vascular system. Vyleesi, is one brand name in which Bremelanotide PT 141 is sold under and is manufactured by Palatin Technologies Inc.
Other names for PT 141 include Rekynda and Bremelanotide acetate.
In 2019, PT 141 Bremelanotide was medically approved for the treatment of hypoactive sexual desire disorder and is the first drug of its kind that works on the central nervous system. The FDA issued a press release after PT 141 was approved, and stated that women experiencing reduced sexual desire due to hypoactive sexual desire disorder, showed clear signs of marked distress.
PT 141 Bremelanotide in Action
The research-proven and efficacious form of PT 141 Bremelanotide, is administered by subcutaneous injection. Alternatively, PT 141 Bremelanotide is available in several other forms which include, nasal spray and capsules for those wanting to stay away from the injectable. Companies that market PT 141 as topical creams have no documented efficacy and should not be used. The most appropriate injection sites are areas of the body where there are fat deposits, such as the lower abdomen or stomach, glutes, and thigh.
The most common minimum effective dose for PT 141 Bremelanotide, is 2mg for both men and women, but the dosage can be adjusted in the event of certain medical conditions or issues. You should consult your physician or health care provider who can look at review your medical history prior to using PT 141. Additionally, in hypersensitive individuals, a cycling protocol may be administered where smaller microdoses are given for a specific period of time in order to find an optimal dose. PT 141 Bremelanotide has a very quick response time and can begin to affect in minutes in many cases. Generally, the effect of PT 141 Bremelanotide can last up to 72 hours.
As an added bonus, PT 141 Bremelanotide can make your skin tan, as if you had been at the beach!
PT 141 Bremelanotide Benefits
Erectile dysfunction or ED is described as not having the ability to achieve or sustain an erection of the penis in order to allow pleasurable sexual intercourse. Erectile dysfunction can occur as a result of neurogenic, psychogenic and/or vascular disorders. In the United States, it has been reported that ED affects between 12 to 35 million men and greater than 150 million men worldwide.
According to the American Sexual Health Association, hypoactive sexual desire disorder in women is described as a lack of sexual thoughts, fantasies, and/or desire for interest in sexual activity which causes great personal distress and/or difficulties in her relationship. In women, this sexual disorder can lead to additional physical and psychological concerns.
In treating ED, the objective for the patient to produce an erection for adequate vaginal penetration and sustaining the erection for patient and partner satisfaction. The majority of treatment for ED in the US is through pharmacology. The most prevalent pharmacological treatment for ED is sildenafil, also known under the brand name Viagra. Sildenafil success rates vary between 45 to 70% and are dependent on cause and severity. Other commonly prescribed ED medicines include vardenafil, under the brand name Levitra and tadalafil under the name brand Cialis.
PT 141 Bremelanotide, the newest approved treatment for women suffering from hypoactive sexual desire disorder and men suffering from ED. PT 141, also appears to have the least amount of side effects.
PT 141 Bremelanotide provides many primary benefits that you can see and feel from the first use.
The benefits of PT 141 Bremelanotide include:
- Higher sex drive and increased sexual desire.
Greater sexual frequency.
Clinically researched and approved treatment for erectile dysfunction and/or impotence.
Effective treatment for premenopausal women with Hypoactive Sexual Disorder.
Increased levels of natural energy
Effective sunless tanner without the dangerous effects of overexposure to the sun, tanning beds or sunless tanners.
Additionally, PT 141 offers numerous secondary benefits that while you may not see from the initial use, build up in your body and improve your overall health.
Secondary benefits of PT 141 include:
Improved mental and physical well-being.
Immune system improvement.
Increase bladder control and greater pelvic floor muscle strength in women.
Lower the risk of heart attack and/or stroke in men as a result of increased sexual activity.
What You Should Know Before Using PT 141
Consult Your Healthcare Provider Before Using PT 141 Bremelanotide if you have any of the following:
History of high blood pressure and/or cardiovascular disease.
If you are hypertensive and are currently not having it treated by a physician.
Any kidney issues.
Any liver issues.
Currently pregnant or planning on becoming pregnant.
Some of the reported side effects of using PT 141 Bremelanotide include the following:
Temporary increase in blood pressure and/or a decrease in heart rate, lessening as the injection wears off.
Focal pigmentation (darkening) of the skin in certain areas of the body.
Brief nausea, which lessens severity quickly.
Slight flushing, skin reaction at the injection site, headache, cough and nasal congestion.